Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Lung nucleosomes containing histone 3.1: a new biomarker for monitoring asthma response to mepolizumab?

Wednesday, February 28, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at GREMI 2023 by Granger et al. discusses lung nucleosomes containing histone 3.1 as a potential new biomarker for monitoring asthma response to mepolizumab. This research may enhance the understanding of treatment efficacy in asthma patients. The findings could lead to improved monitoring strategies in clinical settings.
Price reaction · baseline $20.27 (2024-02-28T16:21:00.000Z) · hit during market hours · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a potential new biomarker for asthma monitoring.
  • Research presented at a notable conference (GREMI 2023).

Full Press Release Details

Poster titled: Lung nucleosomes containing histone 3.1: a new biomarker for monitoring asthma response to mepolizumab?
Presented at GREMI 2023
Granger et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the new biomarker discussed in the article?

The new biomarker discussed is lung nucleosomes containing histone 3.1.

Where was the research on histone 3.1 presented?

The research was presented at GREMI 2023.

What condition is the biomarker intended to monitor?

The biomarker is intended to monitor asthma response to mepolizumab.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare asthma mepolizumab biomarker GREMI 2023
Last updated: Feb 28, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk